Table 2.
Primary and secondary endpoints after 3 months *.
| Endpoint | AI-Guided Group (n = 34) (% Change from Baseline (95% CI)) |
Physician-Guided Group (n = 33) (% Change from Baseline (95% CI)) |
% Difference (95% CI) | p-Value |
|---|---|---|---|---|
| LDL-C | −25.3% (−28.7%, −21.9%) | −15.2% (−18.5%, −11.9%) | −10.1% (−15.5%, −4.7%) | p < 0.01 |
| Total cholesterol | −15.4% (−19.1%, −11.7%) | −8.1% (−11.5%, −4.7%) | −7.3% (−12.3%, −2.3%) | p < 0.05 |
| HDL-C | 6.2% (3.1%, 9.3%) | 4.3% (1.2%, 7.4%) | 1.9% (−2.1%, 5.9%) | p = 0.30 |
| Triglycerides | −22.1% (−27.2%, −17.0%) | −12.3% (−16.7%, −7.9%) | −9.8% (−16.8%, −2.8%) | p < 0.01 |
| hsCRP | −12.5% (−20.4%, −4.6%) | −5.3% (−12.4%, 1.8%) | −7.2% (−15.2%, 0.8%) | p = 0.10 |
* Data are expressed as the mean percent change from baseline (95% confidence interval). Percent changes in LDL-C levels from baseline to the end of the study were compared using independent t-tests. Secondary endpoints (hsCRP, HDL-C, TC, and TG) were analyzed using a two-way ANOVA with treatment and genotype as factors, followed by post-hoc tests with Bonferroni correction for multiple comparisons. Abbreviations: LDL-C, low-density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; HDL-C, high-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides.